Pauwels R.A., Buist A.S., Calverley P.M., Jenkins C.R., Hurd S.S. GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256–1276. https://doi.org/10.1164/ajrccm.163.5.2101039..
DOI: 10.1164/ajrccm.163.5.2101039
Terry P.D., Dhand R. Inhalation Therapy for Stable COPD: 20 Years of GOLD Reports. Adv Ther. 2020;37(5):1812–1828. https://doi.org/10.1007/s12325-020-01289-y..
DOI: 10.1007/s12325-020-01289-y
Williams D.M., Rubin B.K. Clinical Pharmacology of Bronchodilator Medications. Respir Care. 2018;63(6):641–654. https://doi.org/10.4187/respcare.06051..
DOI: 10.4187/respcare.06051
Johnson M., Rennard S. Alternative mechanisms for long-acting β2-adrenergic agonists in COPD. Chest. 2001;120(1):258–270. https://doi.org/10.1378/chest.120.1.258..
DOI: 10.1378/chest.120.1.258
Hanania N.A., Moore R.H. Anti-inflammatory activities of β2-agonists. Curr Drug Targets Inflamm Allergy. 2004;3(3):271–277. https://doi.org/10.2174/1568010043343598..
DOI: 10.2174/1568010043343598
Bestall J.C., Paul E.A., Garrod R., Garnham R., Jones P.W., Wedzicha J.A. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–586. https://doi.org/10.1136/thx.54.7.581..
DOI: 10.1136/thx.54.7.581
Miravitlles M., Soler-Cataluña J.J., Calle M., Molina J., Almagro P., Quintano J.A., Trigueros J.A. et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. Arch Bronconeumol. 2017;53(6):324–335. https://doi.org/10.1016/j.arbres.2017.03.018..
DOI: 10.1016/j.arbres.2017.03.018
Aisanov Z., Avdeev S., Arkhipov V., Belevskiy A., Chuchalin A., Leshchenko I. et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int J Chron Obstruct Pulmon Dis. 2018;13:183–187. https://doi.org/10.2147/COPD.S153770..
DOI: 10.2147/COPD.S153770
Cazzola M., Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257–267. https://doi.org/10.1016/j.pupt.2010.03.003..
DOI: 10.1016/j.pupt.2010.03.003
Price D., Ǿstrem A., Thomas M., Welte T. Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review. Int J COPD. 2017;12:141–168. https://doi.org/10.2147/COPD.S116719..
DOI: 10.2147/COPD.S116719
Rodrigo G.J., Price D., Anzueto A., Singh D., Altman P., Bader G., et al. LABA/ LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J COPD. 2017;12:907–922. https://doi.org/10.2147/COPD.S130482..
DOI: 10.2147/COPD.S130482
Skolnik N.S., Nguyen T.S., Shrestha A., Ray R., Corbridge T.C., Brunton S.A. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators. Postgrad Med. 2020;132(2):198–205. https://doi.org/10.1080/00325481.2019.1702834..
DOI: 10.1080/00325481.2019.1702834
Jones P.W., Quirk F.H., Baveystock C.M., Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145(6):1321–1327. https://doi.org/10.1164/ajrccm/145.6.1321..
DOI: 10.1164/ajrccm/145.6.1321
Singh D., Criner G.J., Naya I., Jones P.W., Tombs L., Lipson D.A., Han M.K. Measuring disease activity in COPD: is clinically important deterioration the answer? Respir Res. 2020;21(1):134. https://doi.org/10.1186/s12931-020-01387-z..
DOI: 10.1186/s12931-020-01387-z
Naya I., Compton C., Ismaila A.S., Birk R., Brealey N., Tabberer M. et al. Preventing clinically important deterioration with single-inhaler triple therapy in COPD. ERJ Open Res. 2018;4(4):00047–2018. https://doi.org/10.1183/23120541.00047-2018..
DOI: 10.1183/23120541.00047-2018
Rabe K.F., Halpin D.M.G., Han M.K., Miravitlles M., Singh D., Grönke L. et al. Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. Respir Res. 2020;21(1):177. https://doi.org/10.1186/s12931-020-01431-y..
DOI: 10.1186/s12931-020-01431-y
Han M.K., Criner G.J., Dransfield M.T., Halpin D.M.G., Jones C.E., Kilbride S. et al. Prognostic value of clinically important deterioration in COPD:IMPACT trial analysis. ERJ Open Res. 2021;7(1):00663–2020. https://doi.org/10.1183/23120541.00663-2020..
DOI: 10.1183/23120541.00663-2020
Maleki-Yazdi M.R., Singh D., Anzueto A., Tombs L., Fahy W.A., Naya I. Assessing short-term deterioration in maintenance-naive patients with COPD receiving umeclidinium/vilanterol and tiotropium: a pooled analysis of three randomized trials. Adv Ther. 2016;33(12):2188–2199. https://doi.org/10.1007/s12325-016-0430-6..
DOI: 10.1007/s12325-016-0430-6
Bjermer L.H., Boucot I.H., Vogelmeier C.F., Maltais F., Jones P.W., Tombs L. et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomized trial. Adv Ther. 2021;38(9):4815–4835. https://doi.org/10.1007/s12325-021-01855-y..
DOI: 10.1007/s12325-021-01855-y
Feldman G., Walker R.R., Brooks J., Mehta R., Crater G. 28-Day safety, and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2012;25(6):465–471. https://doi.org/10.1016/j.pupt.2012.08.007..
DOI: 10.1016/j.pupt.2012.08.007
Kerwin E., Ferguson G.T., Sanjar S., Goodin T., Yadao A., Fogel R. et al. Dual bronchodilation with indacaterol Maleate/Glycopyrronium bromide compared with umeclidinium bromide/vilanterol in patients with moderate-tosevere COPD: results from two randomized, controlled, cross-over studies. Lung. 2017;195(6):739–747. https://doi.org/10.1007/s00408-017-0055-9..
DOI: 10.1007/s00408-017-0055-9
Feldman G.J., Sousa A.R., Lipson D.A., Tombs L., Barnes N., Riley J.H et al. Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther. 2017;34(11):2518–2533. https://doi.org/10.1007/s12325-017-0626-4..
DOI: 10.1007/s12325-017-0626-4
Calzetta L., Rogliani P., Matera M.G., Cazzola M. A Systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149(5):1181–1196. https://doi.org/10.1016/j.chest.2016.02.646..
DOI: 10.1016/j.chest.2016.02.646
Bjermer L., Boucot I.H., Maltais F., Kerwin E.M., Naya I.P., Tombs L. et al. Dual bronchodilator therapy as first-line treatment in maintenance-naive patients with symptomatic COPD: A pre-specified analysis of the EMAX trial. Int J COPD. 2021;16:1939–1956. https://doi.org/10.2147/COPD.S291751..
DOI: 10.2147/COPD.S291751
Matera M.G., Page C.P., Calzetta L., Rogliani P., Cazzola M. Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev. 2020;72(1):218–252. https://doi.org/10.1124/pr.119.018150..
DOI: 10.1124/pr.119.018150
Singh D., Donohue J.F., Boucot I.H., Barnes N.C., Compton C., Martinez F.J. Future concepts in bronchodilation for COPD: dual-versus monotherapy. Eur Respir Rev. 2021;30(160):210023. https://doi.org/10.1183/16000617.0023-2021..
DOI: 10.1183/16000617.0023-2021
Chen H., Wang K., Yuan T., Wang X., Huanng L., Jiang Z. et al. Dual bronchodilator versus inhaled corticosteroid/long-acting β2-agonist in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials. Int Immunopharmacol. 2021;93:107447. https://doi.org/10.1016/j.intimp.2021.107447..
DOI: 10.1016/j.intimp.2021.107447
Mammen M.J., Lloyd D.R., Kumar S., Ahmed A.S., Pai V, Kunadharaju R. et al. Triple therapy versus dual or monotherapy with long-acting bronchodilators for COPD: A systematic review and meta-analysis. Ann Am Thorac Soc. 2020;17(10):1308–1318. https://doi.org/10.1513/AnnalsATS.202001-023OC..
DOI: 10.1513/AnnalsATS.202001-023OC
Bafadhel M., Peterson S., De Blas M.A., Calverley P.M., Rennard S.I., Richter K., Fagerås M. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomized trials. Lancet Respir Med. 2018;6(2):117–126. https://doi.org/10.1016/S2213-2600(18)30006-7..
DOI: 10.1016/S2213-2600(18)30006-7
Gibson P.G. Variability of blood eosinophils as a biomarker in asthma and COPD. Respirology. 2017;23(1):12–13. https://doi.org/10.1111/resp.13200..
DOI: 10.1111/resp.13200
Papaioannou A.I., Loukides S., Bakakos P., Kosmas E.N., Rovina N., Steiropoulos P. et al. Dual bronchodilator in the era of triple therapy. Int J COPD. 2020;15:2695–2705. https://doi.org/10.2147/COPD.S273987.
DOI: 10.2147/COPD.S273987